t74719.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549
 
SCHEDULE 13G
 
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*

 
Horizon Pharma Public Limited Company
(Name of Issuer)
 
Ordinary Shares, nominal value $0.0001 per share
(Title of Class of Securities)
 
 
G4617B105
(CUSIP Number)
 
 
December 31, 2014
(Date of Event Which Requires Filing of This Statement)
 
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o           Rule 13d-1(b)
 
ý           Rule 13d-1(c)
 
o           Rule 13d-1(d)
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
CUSIP No.  G4617B105
 
13G
Page 2 of  7 Pages
1
NAMES OF REPORTING PERSONS
 
Christoph F. Boehringer
2
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 
 
                                                                                                   
(a)       ¨
(b)       ý    
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Germany
NUMBER OF
SHARES
BENEFICIALLY 
OWNED BY
EACH REPORTING 
PERSON WITH
5
SOLE VOTING POWER
 
1,000,000
  
6
SHARED VOTING POWER
 
2,250,000
    
7
SOLE DISPOSITIVE POWER
 
1,000,000
      
8
SHARED DISPOSITIVE POWER
 
2,250,000
      
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,250,000
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
2.7%
12
TYPE OF REPORTING PERSON
 
IN
 
 
 
 
 
 
CUSIP No.  G4617B105
 
13G
Page 3 of 7 Pages
1
NAMES OF REPORTING PERSONS
 
CD-Venture GmbH
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a)       ¨
(b)       ý
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Germany
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH
5
SOLE VOTING POWER
 
2,250,000
  
6
SHARED VOTING POWER
 
0
    
7
SOLE DISPOSITIVE POWER
 
2,250,000
      
8
SHARED DISPOSITIVE POWER
 
0
      
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,250,000
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
¨
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
1.9%
12
TYPE OF REPORTING PERSON
 
CO
 
 
 
 
CUSIP No.  G4617B105
 
13G
Page 4 of 7 Pages

Item 1(a).
Name of Issuer:
 
Horizon Pharma Public Limited Company
 
Item 1(b).
Address of Issuer’s Principal Executive Offices:
 
Adelaide Chambers
Peter Street, Dublin 8
Ireland
 
Item 2(a).
Name of Person Filing:
 
This Statement on Schedule 13G (this “Statement”) is filed by CD-Venture GmbH (“CD-Venture”) and Christoph F. Boehringer.
 
Item 2(b).
Address of Principal Business Office or, if none, Residence:
 
Bergheimer Str. 45
69115 Heidelberg
Germany
 
Item 2(c).
Citizenship:
 
CD-Venture is a German corporation.  Mr. Boehringer is a German citizen.
 
Item 2(d).
Title of Class of Securities:
 
Ordinary Shares, nominal value $0.0001 per share (the "Ordinary Shares")
 
Item 2(e).
CUSIP Number:  G4617B105
 
Item 3. 
Not applicable.
 
Item 4. 
Ownership.
 
 
(a) 
Amount Beneficially Owned as of December 31, 2014:
 
Mr. Boehringer.  Mr. Boehringer is the beneficial owner of 3,250,000 Ordinary Shares, including 2,250,000 Ordinary Shares beneficially owned by CD-Venture.
 
CD-Venture. CD-Venture is the beneficial owner of 2,250,000 Ordinary Shares.
 
The percentages used herein are based upon 118,852,790 Ordinary Shares outstanding as of November 3, 2014, as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, as filed with the Securities and Exchange Commission on November 6, 2014.
 
 
 
 
 
CUSIP No.  G4617B105
 
13G
Page 5 of 7 Pages
 
 
 
 
(b) 
Percent of Class:
 
Christoph F. Boehringer
2.7%*
CD-Venture
1.9%
 *Includes shares beneficially owned by CD-Venture.

 
(c) 
Number of shares as to which such person has:
 
 
(i) 
sole power to vote or to direct the vote:
 
Christoph F. Boehringer
1,000,000
CD-Venture
2,250,000

 
(ii) 
shared power to vote or to direct the vote:
 
Christoph F. Boehringer
2,250,000*
  
CD-Venture
0
  
*Consists of shares beneficially owned by CD-Venture with respect to which Mr. Boehringer shares the power to direct the vote.
 
  
 
(iii) 
sole power to dispose or to direct the disposition of:
 
Christoph F. Boehringer
1,000,000
CD-Venture
2,250,000

 
(iv) 
shared power to dispose or direct the disposition of:
 
Christoph F. Boehringer
2,250,000*
CD-Venture
0
 *Consists of shares beneficially owned by CD-Venture with respect to which Mr. Boehringer shares the power to direct the disposition.
 
 
 

 
CUSIP No.  G4617B105
 
13G
Page 6 of 7 Pages
 
Item 5. 
Ownership of Five Percent or Less of a Class.
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  ☒
 
Item 6. 
Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
Not applicable.
 
Item 8. 
Identification and Classification of Members of the Group.
 
Not applicable.
 
Item 9. 
Notice of Dissolution of Group.
 
Not applicable.
 
Item 10. 
Certification.
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
 
 
 

CUSIP No.  G4617B105
 
13G
Page 7 of 7 Pages
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 

Date:
 February 17, 2015    
     
     
     
/s/ Christoph F. Boehringer  
Christoph F. Boehringer
  
 
 
 
CD-Venture GmbH
  
     
     
By:
 /s/ Christoph F. Boehringer  
 
Christoph F. Boehringer, Geschäftsführer (Managing Director)